An observational study in Cancer, sponsored by Institut Bergonié. Completed at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Institut Bergonié · Observational
The growing incidence of cancer associated to an aging population represents an epidemiologic reality that requires questioning access to care and prognosis in elderly with cancer, for which disparities have been highlighted. However, generally speaking, studies are limited in that they overlook geriatric-specific factors. The aim of this work was to study sociodemographic, socioeconomic and clinical determinants of access to care (cancer stage, cancer treatment) and prognosis (functional decline, survival) in elderly cancer patients.
The French department of Gironde (1.5 million inhabitants) is covered by cancer registries. In addition, three cohorts were initiated in Gironde on cerebral and functional aging that enrolled subjects aged 65 years and over: the PAQUID study (1988), the 3-City study (1999), and the AMI study (2007). In these cohorts, a large amount of individual data on the participants has been collected longitudinally at different follow-up visits, conducted every two or three years.
Using cancer registries, older subjects with cancer were identified in the cohort studies. Subjects were included if they presented the following: i) aged 65 years and over from one of the three cohorts, ii) alive on January 1st 2005 (common start date for tumor recording) and resident in Gironde, and iii) with a validated cancer diagnosis recorded in one of the cancer registries from January 1st 2005 to December 31st 2014. All tumors for which data is annually sent by cancer registries to the International Agency for Research of Cancer were included: invasive malignant tumors and benign tumors of the central nervous system. As the incidence of skin tumors in older cancer patients is high, they were also included. For patients with multiple tumors, only one was considered: either the first one diagnosed if there were several tumors with a minimum of a 6 months interval between their diagnosis, or the one with the worse prognosis if there were several tumors diagnosed within 6 months.
In order to not consider information concerning patients' characteristics that was too old, subjects with a delay between the last completed cohort follow-up visit before the cancer diagnosis and the diagnosis of cancer equal or superior to 6 years were excluded.
Variables were extracted from cohorts and registries at different times: cohort inclusion, pre-diagnosis visit, cancer diagnosis or registries follow-up.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 450 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Institut Bergonié is the lead sponsor of 119 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects aged 65 and over with a diagnosis of cancer recorded in one of the cancer registries in Gironde, French department.
Subjects i) aged 65 years and over from the PAQUID, the 3City or the AMI study; ii) alive on January 1st 2005 (common start date of tumor recording); iii) resident in Gironde; and iv) with a validated cancer diagnosis recorded in one of the cancer registries from January 1st 2005 to December 31st 2014. We included all invasive malignant tumors (including skin tumors) and benign tumors of the central nervous system. For patients with multiple tumors, only one was considered: i) the first one diagnosed if there were several tumors with a minimum of a 6 months interval between their diagnosis, ii) the one with the worse prognosis if there were several tumors diagnosed within less than 6 months.
Other: Any cancer treatment
Proportion of Patients Being Receiving Treatment Administration After Diagnosis
Treatment administration was defined as any cancer treatment (versus no treatment) including curative, palliative and symptomatic treatments. This information was registered by registries and qualified as unknown when no information was available about treatment receipt.
Time frame: At diagnosis
The Probability of Being Dead at One Year
The probability of being dead with or without receiving cancer treatment at least once (death)
Time frame: one year after diagnosis
| Milestone | Older Patients With Cancer |
|---|---|
| Started | 450 |
| Completed | 450 |
| Not completed | 0 |
Treatment administration was defined as any cancer treatment (versus no treatment) including curative, palliative and symptomatic treatments. This information was registered by registries and qualified as unknown when no information was available about treatment receipt.
| Participants | Older Patients With Cancer |
|---|---|
| Proportion of Patients Being Receiving Treatment Administration After Diagnosis | 372 |
The probability of being dead with or without receiving cancer treatment at least once (death)
| percentage of participants | Older Patients With Cancer |
|---|---|
| The Probability of Being Dead at One Year | 35.5 |
Collected over One year Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Older Patients With Cancer | 160/450 (35.6%) | — | — |
| Age, Categorical(Participants) | Older Patients With Cancer |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 0 |
| >=65 years | 450 |
| Sex: Female, Male(Participants) | Older Patients With Cancer |
|---|---|
| Female | 204 |
| Male | 246 |
| Region of Enrollment(participants) | Older Patients With Cancer |
|---|---|
| France | 450 |
Plan to share: No
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Bergonié